The FDA approved re-administration of iDose TR for patients with healthy corneas, enhancing treatment flexibility for ...

STAMFORD, Conn.--(BUSINESS WIRE)--TECLens, Inc., a clinical-stage ophthalmic medical device company, announced today it raised $9.3 million in a Series A round co-led by Johnson & Johnson Innovation – ...

The program looks to address shortage of veterinary ophthalmologists that impacts availability and wait times for eye care, ...

Centre for Sight enhances eye care across the region, offering advanced services and a multi-centre network to ensure comprehensive patient support.

Glaukos Corporation , an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.

Conference Call and Webcast Scheduled for 1:30 p.m. PTALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), ...

The Seattle Seahawks are expecting standout left tackle Charles Cross to return for their playoff run, and now he'll do so with a new contract. The Seahawks and Cross have agreed to terms on a ...

Seattle Seahawks offensive tackle Charles Cross has reportedly come to terms on a four-year, $104.4 million contract. Cross' extension is the largest contract in Seahawks history for a non-quarterback ...

A day after securing the No. 1 seed in the NFC playoffs, the Seattle Seahawks secured the future of one of their brightest young players. Offensive tackle Charles Cross agreed to a four-year, $104.4 ...

Corneal trauma can cause significant ocular morbidity and visual difficulty. Prompt diagnosis and management is required to prevent these complications. Although open globe injuries are uncommon, ...